Ines B. Menjak

ORCID: 0000-0002-4239-0858
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Frailty in Older Adults
  • Palliative Care and End-of-Life Issues
  • Nutrition and Health in Aging
  • Lung Cancer Treatments and Mutations
  • Cancer survivorship and care
  • Breast Cancer Treatment Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Lung Cancer Diagnosis and Treatment
  • Management of metastatic bone disease
  • CAR-T cell therapy research
  • Global Cancer Incidence and Screening
  • Cancer Immunotherapy and Biomarkers
  • Brain Metastases and Treatment
  • Cancer Treatment and Pharmacology
  • Biosimilars and Bioanalytical Methods
  • Lung Cancer Research Studies
  • Advanced Breast Cancer Therapies
  • Cardiac, Anesthesia and Surgical Outcomes
  • Economic and Financial Impacts of Cancer
  • Cardiac Arrest and Resuscitation
  • Venous Thromboembolism Diagnosis and Management
  • Esophageal and GI Pathology
  • Congenital Heart Disease Studies
  • Colorectal Cancer Treatments and Studies
  • Patient-Provider Communication in Healthcare

Health Sciences Centre
2016-2025

Sunnybrook Health Science Centre
2016-2025

University of Toronto
2013-2025

Pediatric Oncology Group
2016-2021

Juravinski Cancer Centre
2018

McMaster University
2011-2018

Hospital for Sick Children
2009-2018

Trillium Health Centre
2017

North York General Hospital
2017

Toronto Public Health
2011

PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...

10.1200/jco.23.02747 article EN Journal of Clinical Oncology 2024-08-22
Myung‐Ju Ahn Kentaro Tanaka Luís Paz-Ares Robin Cornelissen Nicolas Girard and 95 more Elvire Pons‐Tostivint David Vicente Baz Shunichi Sugawara Manuel Cobo M. Pérol Céline Mascaux Elena Poddubskaya Satoru Kitazono Hidetoshi Hayashi Min Hee Hong Enriqueta Felip Richard D. Hall Óscar Juan Daniel Brungs Shun Lü Marina Chiara Garassino Michael Chargualaf Yong Zhang Paul Howarth Deise Uema Aaron Lisberg Jacob Sands Gastón L. Martinengo Juan Puig Daniel Brungs Bo Gao Adnan Nagria Christos S. Karapetis Sagun Parakh Cheol Park Gaëtan Catala Frédéric Forget Sebahat Ocak Naveen S. Basappa Geoffrey Liu Ines B. Menjak Benjamin Shieh Shun Lü Feng Luo Hongmei Sun Jialei Wang Yu Yao Milada Zemanová Jaafar Bennouna Nicolas Girard Laurent Greillier Corinne Lamour H. Léna Céline Mascaux Julien Mazières Denis Moro‐Sibilot M. Pérol Elvire Pons‐Tostivint Virginie Westeel Akin Atmaca Christine Greil Niels Reinmuth Christian Schumann Thomas Wehler Juergen Wolf James Ho Csaba Böcskei Federico Cappuzzo Filippo de Marinis Claudia Proto Manlio Mencoboni Silvia Novello Stefania Salvagni Héctor Soto Parrà Haruko Daga Yasushi Goto Hidetoshi Hayashi Satoru Kitazono Kiyotaka Yoh Ryo Ko Masashi Kondo Toshiyuki Kozuki Takayasu Kurata Hideaki Mizutani Kadoaki Ohashi Satoshi Oizumi Isamu Okamoto Satoshi Sakaguchi H Ozasa Shunichi Sugawara Yuichi Tambo Motohiro Tamiya Hiroshi Tanaka Isamu Okamoto Froylán López-López Francisco Javier Ramirez Godinez Jerónimo Rafael Rodríguez Cid Robin Cornelissen Steven Gans Jos A. Stigt

PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS Patients received Dato-DXd 6 mg/kg or 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) overall (OS). Objective response rate, duration response, secondary points. RESULTS In total, 299 305 randomly...

10.1200/jco-24-01544 article EN Journal of Clinical Oncology 2024-09-09

Thrombosis, usually considered a serious but rare complication of pediatric cardiac surgery, has not been major clinical and/or research focus in the past.We noted 444 thrombi (66% occlusive, 60% symptomatic) 171 1542 surgeries (11%). Factors associated with increased odds thrombosis were age <31 days (odds ratio [OR], 2.0; P=0.002), baseline oxygen saturation <85% (OR, P=0.001), previous 2.6; heart transplantation 4.1; P<0.001), use deep hypothermic circulatory arrest 1.9 P=0.01), longer...

10.1161/circulationaha.110.006304 article EN Circulation 2011-09-13

PURPOSE American Society of Clinical Oncology recommends that older adults with cancer being considered for chemotherapy receive geriatric assessment (GA) and management (GAM), but few randomized controlled trials have examined its impact on quality life (QOL). PATIENTS AND METHODS The 5C study was a two-group parallel 1:1 single-blind multicenter trial GAM 6 months versus usual oncologic care. Eligible patients were age 70+ years, diagnosed solid tumor, lymphoma, or myeloma, referred...

10.1200/jco.22.01007 article EN Journal of Clinical Oncology 2022-12-06

Purpose: Optimal first-line systemic therapy for patients with advanced nonsquamous (nonsq) non–small-cell lung cancer (NSCLC) requires confirmation of EGFR/ ALK status, which can delay treatment. We evaluated the impact reflex testing, defined as pathologists initiating testing at time diagnosis nonsq NSCLC, on to treatment (TTT). Methods: conducted a retrospective review NSCLC medical oncology consultation Sunnybrook Odette Cancer Centre between March 18, 2010 and April 30, 2014. Data were...

10.1200/jop.2016.014019 article EN Journal of Oncology Practice 2017-02-01

Older adults with cancer tend to face more complex health needs than their younger counterparts. Patients &gt; 65 years of age are recommended for comprehensive geriatric assessment (CGA) capture and address age-related vulnerabilities. Access geriatrics services is limited, our baseline audit referrals in 2019 from the program revealed that only 30% patients referred received a CGA. The aim this study was assess implementation oncology (GO) clinic employs CGA determine patient outcomes. We...

10.3390/curroncol32020089 article EN cc-by Current Oncology 2025-02-06

<h3>Importance</h3> Cancer care has inherent complexities in older adults, including balancing risks of cancer and noncancer death. A poor understanding cause-specific outcomes may lead to overtreatment undertreatment. <h3>Objective</h3> To examine all-cause cancer-specific death throughout 5 years for adults after resection. <h3>Design, Setting, Participants</h3> This population-based cohort study was conducted Ontario, Canada, using the administrative databases stored at ICES (formerly...

10.1001/jamasurg.2021.1425 article EN JAMA Surgery 2021-05-12

Objective: We sought to identify factors that can predict esophageal cancer (EC) patients at high risk of requiring feeding tube insertion. Methods: A retrospective cohort review was conducted, including all diagnosed with EC our center from 2013 2018. Multivariate logistic regression performed comparing the group required a reactive insertion those who did not require any factors. Results: total 350 were included in study, and 132/350 (38%) received tube. 50 out 132 had inserted reactively....

10.1080/01635581.2024.2301796 article EN Nutrition and Cancer 2024-01-11

Abstract Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with efficacy results. As such it important to understand a treatment’s real-world effectiveness. We examined population-based comparative of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments). Methods used cohort melanoma patients receiving systemic treatment for advanced disease since April 2005 from Ontario, Canada. Patients were identified...

10.1186/s12885-020-06798-1 article EN cc-by BMC Cancer 2020-04-15

Abstract Background and purpose This study aimed to summarize the clinical outcomes of patients with metastatic melanoma who received high‐dose radiation prior or during systemic therapy at a single academic institution. Methods We identified underwent (HDRT) for extracranial metastases from 2010 2018. Treatment indications included oligometastases, oligoprogression, local control. Using Kaplan‐Meier method, we plotted overall survival (OS), progression‐free survival‐1 (PFS1), PFS2....

10.1002/pro6.1224 article EN cc-by-nc-nd Precision Radiation Oncology 2024-03-24

Geriatric assessment and management (GAM) is recommended by professional organizations recently several randomized controlled trials (RCTs) demonstrated benefits in multiple health outcomes. GAM typically leads to one or more recommendations for the older adult on how optimize their health. However, little known about well are adhered to. Understanding these issues vital designing clinical programs. Therefore, aim of this study was examine number made adherence satisfaction with intervention...

10.1016/j.jgo.2023.101586 article EN cc-by-nc-nd Journal of Geriatric Oncology 2023-07-15
Coming Soon ...